全网公布的罗氟司特2025年最新价格

Roflumilast is a drug used to treat chronic obstructive pulmonary disease (COPD), and its price in 2025 will vary in different regions. The German version of roflumilast produced by AstraZeneca in the UK is more expensive, while the Hong Kong version is relatively more economical. The drug has been approved for marketing in many countries around the world and has wide clinical applications. Before using roflumilast, patients need to understand its indications, dosage adjustments and possible side effects so that they can use the drug rationally.

The latest price of roflumilast in 2025 published on the entire network

The price changes due to different production regions and specifications. In 2025, there is a significant price difference between the German version and the Hong Kong version of roflumilast produced by AstraZeneca in the UK. Patients can choose the appropriate version according to their needs.

British AstraZeneca German version

The German version of roflumilast is produced by British AstraZeneca. The reference price for a box of 500μg*30 tablets is about US$233, and the price for a box of 90 tablets is about US$391. This version is mainly aimed at the European market and the price is relatively high.

British AstraZeneca Hong Kong version

In the Hong Kong market, the reference price of roflumilast, also produced by British AstraZeneca, is approximately US$134 for 500μg*30 tablets. The Hong Kong version is more economical and suitable for patients with limited budget.

Price differences in different regions may be related to tariffs, transportation costs and local medical policies. Patients need to comprehensively consider price and the reliability of the drug source when choosing.

Global marketing status of Roflumilast

Roflumilast has been approved for marketing in many countries around the world since 2010 and has become one of the important drugs for the treatment of COPD. Its extensive clinical application provides patients with more treatment options.

Approval status in the EU and the United States

Roflumilast tablets were approved for marketing in the EU in July 2010 and approved by the US FDA in March 2011. These approvals mark the official launch of the drug in the European and American markets.

Applications in other countries

Currently, roflumilast has been widely used in Germany, Denmark, the United Kingdom and other countries. Medication guidelines may vary slightly in different countries, but the overall efficacy is recognized.

The global launch of roflumilast provides more treatment opportunities for COPD patients, and its safety and effectiveness have been verified in many countries.

Preparation for the use of roflumilast

Before using roflumilast, patients need to fully understand its indications, usage, dosage and precautions to fully exert the drug's efficacy and reduce adverse reactions.

Indications and Contraindications

Roflumilast is mainly used to treat COPD, but it is not suitable for patients with acute bronchospasm. It is prohibited for those who are allergic to the drug ingredients and should be used with caution by those with liver dysfunction.

Dose adjustment

The conventional dose of roflumilast is 500 μg once a day. Patients with abnormal liver function may need to adjust the dose, and the specific dosage needs to be adjusted according to the doctor's advice.

Rational use of medication is the key to successful treatment. Patients should use roflumilast under the guidance of a doctor and have regular follow-up visits to evaluate efficacy and safety.